Kelly Scaggs Campen
Examiner (ID: 2758, Phone: (571)272-6740 , Office: P/3691 )
Most Active Art Unit | 3691 |
Art Unit(s) | 3624, 2165, 2164, 3312, 3738, 3691 |
Total Applications | 1052 |
Issued Applications | 501 |
Pending Applications | 228 |
Abandoned Applications | 322 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 15711219
[patent_doc_number] => 20200102375
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-02
[patent_title] => Methods of Treating a Tauopathy
[patent_app_type] => utility
[patent_app_number] => 16/398097
[patent_app_country] => US
[patent_app_date] => 2019-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37178
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16398097
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/398097 | Methods of Treating a Tauopathy | Apr 28, 2019 | Abandoned |
Array
(
[id] => 15147833
[patent_doc_number] => 20190352394
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-21
[patent_title] => ENZYMATIC MODIFICATION OF ANTI-AQP4 AUTOANTIBODY FOR MODULATING NEUROMYELITIS OPTICA
[patent_app_type] => utility
[patent_app_number] => 16/397568
[patent_app_country] => US
[patent_app_date] => 2019-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13421
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16397568
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/397568 | ENZYMATIC MODIFICATION OF ANTI-AQP4 AUTOANTIBODY FOR MODULATING NEUROMYELITIS OPTICA | Apr 28, 2019 | Abandoned |
Array
(
[id] => 14993771
[patent_doc_number] => 20190315843
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-17
[patent_title] => ANTIBODIES RECOGNIZING ALPHA-SYNUCLEIN
[patent_app_type] => utility
[patent_app_number] => 16/385968
[patent_app_country] => US
[patent_app_date] => 2019-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17365
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16385968
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/385968 | Antibodies recognizing a-synuclein | Apr 15, 2019 | Issued |
Array
(
[id] => 15209805
[patent_doc_number] => 20190367589
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-05
[patent_title] => ANTI-JAGGED 1/JAGGED 2 CROSS-REACTIVE ANTIBODIES, ACTIVATABLE ANTI-JAGGED ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/376252
[patent_app_country] => US
[patent_app_date] => 2019-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 68201
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16376252
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/376252 | ANTI-JAGGED 1/JAGGED 2 CROSS-REACTIVE ANTIBODIES, ACTIVATABLE ANTI-JAGGED ANTIBODIES AND METHODS OF USE THEREOF | Apr 4, 2019 | Abandoned |
Array
(
[id] => 16275591
[patent_doc_number] => 10758598
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-01
[patent_title] => TPP-1 formulations and methods for treating CLN2 disease
[patent_app_type] => utility
[patent_app_number] => 16/368091
[patent_app_country] => US
[patent_app_date] => 2019-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 53
[patent_figures_cnt] => 54
[patent_no_of_words] => 16292
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16368091
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/368091 | TPP-1 formulations and methods for treating CLN2 disease | Mar 27, 2019 | Issued |
Array
(
[id] => 15148499
[patent_doc_number] => 20190352727
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-21
[patent_title] => METHOD FOR ANALYZING SOMATIC CELL REPROGRAMMING, AND METHOD FOR SETTING UP QUALITY EVALUATION CRITERIA FOR iPS CELL USING THE METHOD
[patent_app_type] => utility
[patent_app_number] => 16/297612
[patent_app_country] => US
[patent_app_date] => 2019-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11383
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 138
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16297612
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/297612 | METHOD FOR ANALYZING SOMATIC CELL REPROGRAMMING, AND METHOD FOR SETTING UP QUALITY EVALUATION CRITERIA FOR iPS CELL USING THE METHOD | Mar 8, 2019 | Abandoned |
Array
(
[id] => 16582864
[patent_doc_number] => 20210017266
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-21
[patent_title] => METHODS FOR TREATING OCULAR DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/980679
[patent_app_country] => US
[patent_app_date] => 2019-03-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7742
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16980679
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/980679 | METHODS FOR TREATING OCULAR DISEASES | Mar 7, 2019 | Pending |
Array
(
[id] => 14833537
[patent_doc_number] => 20190275169
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-12
[patent_title] => TARGETED IMMUNOSUPPRESSION FOR OPTOGENETIC INTERVENTION
[patent_app_type] => utility
[patent_app_number] => 16/296063
[patent_app_country] => US
[patent_app_date] => 2019-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4660
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16296063
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/296063 | TARGETED IMMUNOSUPPRESSION FOR OPTOGENETIC INTERVENTION | Mar 6, 2019 | Abandoned |
Array
(
[id] => 14808367
[patent_doc_number] => 20190270793
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-05
[patent_title] => Anti-PHF-Tau Antibodies and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 16/291303
[patent_app_country] => US
[patent_app_date] => 2019-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12052
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 327
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16291303
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/291303 | Anti-PHF-tau antibodies and uses thereof | Mar 3, 2019 | Issued |
Array
(
[id] => 16570645
[patent_doc_number] => 20210009651
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-14
[patent_title] => USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION
[patent_app_type] => utility
[patent_app_number] => 16/971288
[patent_app_country] => US
[patent_app_date] => 2019-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25534
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16971288
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/971288 | USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION | Feb 28, 2019 | Pending |
Array
(
[id] => 14777939
[patent_doc_number] => 20190263867
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-29
[patent_title] => TAU PEPTIDES, METHODS OF MAKING, AND METHODS OF USING
[patent_app_type] => utility
[patent_app_number] => 16/288290
[patent_app_country] => US
[patent_app_date] => 2019-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18126
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16288290
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/288290 | TAU PEPTIDES, METHODS OF MAKING, AND METHODS OF USING | Feb 27, 2019 | Abandoned |
Array
(
[id] => 18634949
[patent_doc_number] => 11759520
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-09-19
[patent_title] => Theranostics for protein misfolding diseases
[patent_app_type] => utility
[patent_app_number] => 16/285809
[patent_app_country] => US
[patent_app_date] => 2019-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 39
[patent_no_of_words] => 5427
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 113
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16285809
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/285809 | Theranostics for protein misfolding diseases | Feb 25, 2019 | Issued |
Array
(
[id] => 16512981
[patent_doc_number] => 20200392239
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-17
[patent_title] => USE OF A MULTIMERIC ANTI-DR5 BINDING MOLECULE IN COMBINATION WITH A CHEMOTHERAPEUTIC AGENT FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 16/975438
[patent_app_country] => US
[patent_app_date] => 2019-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21961
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16975438
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/975438 | USE OF A MULTIMERIC ANTI-DR5 BINDING MOLECULE IN COMBINATION WITH A CHEMOTHERAPEUTIC AGENT FOR TREATING CANCER | Feb 24, 2019 | Pending |
Array
(
[id] => 14893871
[patent_doc_number] => 20190290701
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-26
[patent_title] => PHOTORECEPTORS AND PHOTORECEPTOR PROGENITORS PRODUCED FROM PLURIPOTENT STEM CELLS
[patent_app_type] => utility
[patent_app_number] => 16/284565
[patent_app_country] => US
[patent_app_date] => 2019-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21520
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16284565
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/284565 | PHOTORECEPTORS AND PHOTORECEPTOR PROGENITORS PRODUCED FROM PLURIPOTENT STEM CELLS | Feb 24, 2019 | Abandoned |
Array
(
[id] => 14833435
[patent_doc_number] => 20190275118
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-12
[patent_title] => AGENTS DIRECTED AGAINST A CIS RGMA/NEOGENIN INTERACTION OR LIPID RAFTS AND USE OF THE SAME IN METHODS OF TREATMENT
[patent_app_type] => utility
[patent_app_number] => 16/277529
[patent_app_country] => US
[patent_app_date] => 2019-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51129
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16277529
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/277529 | Agents directed against a cis RGMa/neogenin interaction or lipid rafts and use of the same in methods of treatment | Feb 14, 2019 | Issued |
Array
(
[id] => 17695957
[patent_doc_number] => 11369659
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-06-28
[patent_title] => Method of enhancing a brain or cognitive function
[patent_app_type] => utility
[patent_app_number] => 16/270810
[patent_app_country] => US
[patent_app_date] => 2019-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 4289
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16270810
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/270810 | Method of enhancing a brain or cognitive function | Feb 7, 2019 | Issued |
Array
(
[id] => 15150381
[patent_doc_number] => 20190353668
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-21
[patent_title] => BIOMARKERS OF COGNITIVE DYSFUNCTION
[patent_app_type] => utility
[patent_app_number] => 16/265008
[patent_app_country] => US
[patent_app_date] => 2019-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34411
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16265008
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/265008 | Biomarkers of cognitive dysfunction | Jan 31, 2019 | Issued |
Array
(
[id] => 14467821
[patent_doc_number] => 20190185553
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-06-20
[patent_title] => ANTIBODY BASED REAGENT THAT SPECIFICALLY RECOGNIZES TOXIC OLIGOMERIC FORM OF BETA-AMYLOID
[patent_app_type] => utility
[patent_app_number] => 16/265621
[patent_app_country] => US
[patent_app_date] => 2019-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12995
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 163
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16265621
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/265621 | ANTIBODY BASED REAGENT THAT SPECIFICALLY RECOGNIZES TOXIC OLIGOMERIC FORM OF BETA-AMYLOID | Jan 31, 2019 | Pending |
Array
(
[id] => 16793000
[patent_doc_number] => 20210122817
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-29
[patent_title] => ANTI-MS4A6A ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/965675
[patent_app_country] => US
[patent_app_date] => 2019-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45517
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965675
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/965675 | ANTI-MS4A6A ANTIBODIES AND METHODS OF USE THEREOF | Jan 30, 2019 | Abandoned |
Array
(
[id] => 17467679
[patent_doc_number] => 11274147
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-15
[patent_title] => Binding molecules that specifically bind to tau
[patent_app_type] => utility
[patent_app_number] => 16/965565
[patent_app_country] => US
[patent_app_date] => 2019-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 11152
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 553
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965565
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/965565 | Binding molecules that specifically bind to tau | Jan 30, 2019 | Issued |